American Thoracic Society (ATS) - 121st International Conference - 2025

May 16 - 21, 2025

FASENRA (benralizumab)
BREZTRI/TRIXEO
TEZSPIRE (tezepelumab)
tozorakimab (MEDI3506)
AIRSUPRA (albuterol/budesonide)
Respiratory Unbranded

pdf

A randomised controlled trial to assess the effect of benralizumab on structural and lung function changes in patients with severe eosinophilic asthma: design of the CHINOOK study

pdf

Efficacy of benralizumab in reducing cough frequency and improving health-related quality of life in patients with severe eosinophilic asthma in Asia: a post-hoc analysis of the Phase 3 MIRACLE study

pdf

Two-year efficacy and safety of benralizumab in the treatment of eosinophilic granulomatosis with polyangiitis

pdf

Reduction in COPD exacerbations following initiation of benralizumab among patients with asthma and concomitant COPD: results from the ZEPHYR-5 Study

pdf

Benralizumab adherence reduces exacerbations and exacerbation-related medical costs among patients with severe asthma: results from the ZEPHYR-5 study

pdf

Pharmacodynamic effects of benralizumab on eosinophil-related biomarkers in COPD: a biomarker analysis of the GALATHEA study

pdf

Model-based comparison of the pharmacokinetic/pharmacodynamic and eosinophilic response of benralizumab versus depemokimab at 12 weeks

pdf

In silico lung deposition of budesonide/glycopyrrolate/formoterol fumarate in patients with COPD and concomitant asthma

pdf

Systemic exposure of budesonide/glycopyrrolate/formoterol fumarate with hydrofluoroolefin-1234ze versus hydrofluoroalkane-134a propellants administered via metered-dose inhaler with a spacer in healthy adults

pdf

Real-world effectiveness of budesonide/glycopyrrolate/formoterol fumarate on COPD exacerbation-related healthcare utilization and costs: results from the US ARCTOS study

pdf

Reduced COPD exacerbation risk with prompt initiation of budesonide/glycopyrrolate/formoterol fumarate (BGF) after a COPD exacerbation among patients with COPD and concurrent asthma: the MITOS EROS+CP (US) study

pdf

Prompt initiation of Budesonide/Glycopyrrolate/Formoterol Fumarate (BGF) after an exacerbation is associated with reduced exacerbation and cardiopulmonary risk in patients with COPD: The MITOS EROS+CP (US) Study

pdf

Cardiopulmonary risk benefits of budesonide/glycopyrrolate/formoterol fumarate triple therapy: a number needed to treat post hoc analysis of the ETHOS trial

pdf

Effect of tezepelumab on lung function in patients with moderate to very severe chronic obstructive pulmonary disease grouped by baseline blood eosinophil count: results from the Phase 2a COURSE study

pdf

Improvements in St George’s Respiratory Questionnaire domain scores with tezepelumab versus placebo in patients with moderate to very severe chronic obstructive pulmonary disease: results from the Phase 2a COURSE study

pdf

Improvements in asthma exacerbations, lung function, asthma control and health-related quality of life after tezepelumab initiation in patients with severe asthma: interim results from the US phase 4 PASSAGE study

pdf

Efficacy of Tezepelumab in adults with severe, uncontrolled asthma across multiple exacerbation trigger types: the Phase 3 DIRECTION study

pdf

Efficacy of tezepelumab on upper and lower airway outcomes in adults with severe, uncontrolled chronic rhinosinusitis with nasal polyps in patients with and without comorbid asthma: results from the Phase 3 WAYPOINT study

pdf

Effect of tezepelumab on exacerbations in patients with moderate to very severe chronic obstructive pulmonary disease based on inclusion or exclusion of antibiotic use in the definition of moderate exacerbations: data from the Phase 2a COURSE study

pdf

Efficacy of tezepelumab in patients with moderate to very severe chronic obstructive pulmonary disease with and without chronic bronchitis: phase 2a COURSE study

pdf

Effect of tezepelumab on inflammatory biomarker levels and on exacerbation rates by baseline inflammatory biomarker levels in patients with moderate to very severe chronic obstructive pulmonary disease: results from the COURSE study

pdf

Tezepelumab reduces and eliminates OCS use in OCS-dependent patients with severe asthma: primary results from the phase 3b WAYFINDER study

pdf

Safety profile of Tozorakimab (an anti-IL-33 monoclonal antibody): data from the FRONTIER phase 2 program of 1076 patients

pdf

As-needed albuterol-budesonide decreases risk of severe asthma exacerbation in the first three months post-randomization compared to as-needed albuterol in patients treated for moderate-to-severe asthma: MANDALA post-hoc analysis

pdf

Baseline characteristics of patients with asthma initiating albuterol-budesonide rescue: a real-world US claims-based study

pdf

Corticosteroid-associated systemic adverse events in patients on background inhaled corticosteroid maintenance therapy and taking albuterol-budesonide versus albuterol as rescue: post-hoc analysis of MANDALA

pdf

Albuterol-budesonide treatment in acute airway obstruction: patient selection for the ALTA study

pdf

Efficacy of as-needed albuterol-budesonide versus albuterol on systemic corticosteroid exposure in participants with mild asthma: BATURA prespecified analysis

pdf

Corticosteroid-related adverse outcomes and costs in Medicare patients with asthma: A retrospective US administrative claims analysis

pdf

Clinical outcomes of patients with idiopathic or lymphocytic hypereosinophilic syndrome in the United States: a real-world retrospective observational cohort study

pdf

Disease states in patients with eosinophilic granulomatosis with polyangiitis (EGPA) in England: a retrospective observational cohort study

pdf

Real-world treatment patterns in patients with eosinophilic granulomatosis with polyangiitis (EGPA)

pdf

Healthcare resource utilization and associated costs across three health states in patients with eosinophilic granulomatosis with polyangiitis (EGPA): a retrospective observational cohort study in England

pdf

Clinical characteristics and burden of illness in people with COPD experiencing exacerbations while on inhaled triple therapy, stratified by smoking status: the SIRIUS study (US)

pdf

Treatments patterns in US patients hospitalized for viral lower respiratory tract disease: an analysis of linked electronic health records and claims data (2015-2023)

Não encontra o que procura?

Contacte-nos

Encontre um Medical Healthcare Partner

Submeter uma questão